Spots Global Cancer Trial Database for A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Official Title: A Single-Arm, Open-Label, Exploratory Study to Evaluate Safety and Efficacy of LM103 Injection in the Treatment of Advanced Solid Tumors

Study ID: NCT05366478

Conditions

Melanoma

Non Small Cell Lung Cancer

Cervical Carcinoma

Interventions

Autologous tumor infiltrating lymphocytes (TILs)

Study Description

Brief Summary: This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

Detailed Description: This is an investigator initiated , single-arm, open-label ,exploratory study of LM103 Injection in patients with advanced solid tumors. Expanded TILs will be transferred to the patient after chemotherapy with cyclophosphamide and fludarabine. LM103 will be administered as a single dose on day 1. TIL transfer will be combined with IL-2 treatment. This study is planned to enroll 9-15 patients with advanced solid tumors.